Heather Getz Acquires 70,000 Shares of Myomo (NYSEAMERICAN:MYO) Stock

Myomo, Inc. (NYSEAMERICAN:MYO) Director Heather Getz bought 70,000 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were acquired at an average price of $0.73 per share, for a total transaction of $51,100.00. Following the completion of the acquisition, the director owned 111,754 shares in the company, valued at $81,580.42. This represents a 167.65% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Myomo Stock Down 3.7%

NYSEAMERICAN MYO traded down $0.03 during trading on Thursday, reaching $0.69. 469,515 shares of the company’s stock traded hands, compared to its average volume of 513,649. Myomo, Inc. has a 12-month low of $0.64 and a 12-month high of $5.62. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.30 and a quick ratio of 2.10. The firm has a market cap of $26.45 million, a price-to-earnings ratio of -1.86 and a beta of 1.17. The company’s 50 day simple moving average is $0.85 and its two-hundred day simple moving average is $0.92.

Myomo News Roundup

Here are the key news stories impacting Myomo this week:

• Positive Sentiment: Director Heather C. Getz purchased 70,000 shares at an average $0.73, raising her direct ownership to 111,754 shares — a sizable insider buy that can be interpreted as management confidence in the company’s outlook. SEC Filing
• Neutral Sentiment: Q4 2025 earnings call noted record revenue but rising expenses and margin pressure — revenue strength is encouraging for growth, but higher costs weigh on near‑term profitability and cash needs. Earnings Call Highlights
• Neutral Sentiment: HC Wainwright published a long‑range FY2030 estimate (EPS $0.35), which suggests potential long‑term upside if execution and reimbursement trends improve, but this is far‑term and speculative. MarketBeat MYO
• Negative Sentiment: HC Wainwright cut near‑term and multi‑year EPS forecasts across Q1–Q3 2026 and FY2026–FY2029 (e.g., FY2026 to ($0.34) from ($0.31); FY2027 to ($0.22) from ($0.15); FY2028 to ($0.05) from $0.07; FY2029 to $0.16 from $0.30). These downward revisions tighten the outlook and likely pressured the stock. Analyst Note
• Negative Sentiment: Myomo flagged new high‑risk language in forward‑looking statements — highlighting concerns around reimbursement, financing and growth plans — which raises execution and funding risk for investors. Risk Disclosure

Institutional Investors Weigh In On Myomo

Several institutional investors have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd acquired a new position in shares of Myomo during the first quarter worth $75,000. Invesco Ltd. acquired a new stake in shares of Myomo in the 2nd quarter worth $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Myomo during the 2nd quarter worth $38,000. Intech Investment Management LLC purchased a new position in Myomo during the 2nd quarter worth $38,000. Finally, Acadian Asset Management LLC acquired a new position in Myomo during the 1st quarter valued at about $114,000. 44.99% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Craig Hallum restated a “buy” rating on shares of Myomo in a report on Tuesday. Ascendiant Capital Markets reduced their price target on Myomo from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $7.67.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.